NCT02914990View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 29, 2016

Primary Completion Date

March 7, 2019

Study Completion Date

March 7, 2019

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

BPI-15086

BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.

Trial Locations (1)

100021

Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

NCT02914990 - Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients | Biotech Hunter | Biotech Hunter